Marizyme, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
August 23, 2021 at 05:13 pm
Share
Marizyme, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced sales was USD 160,785. Operating loss was USD 2.456 million compared to USD 434,911 a year ago. Net loss was USD 2.460 million compared to USD 434,911 a year ago. Basic loss per share from continuing operations was USD 0.07 compared to USD 0.02 a year ago. For the half year, sales was USD 234,737. Operating loss was USD 5.267 million compared to USD 906,281 a year ago. Net loss was USD 5.271 million compared to USD 906,281 a year ago. Basic loss per share from continuing operations was USD 0.15 compared to USD 0.05 a year ago.
Marizyme, Inc. is a medical technology company. The Company is focused on cardiac and surgical care by delivering innovative solutions for coronary artery bypass graft (CABG) surgery and other surgical procedures. Its product DuraGraft, is a one-time intraoperative vascular graft treatment for use in vascular and bypass surgeries that maintains endothelial function and structure, thereby reducing the incidence and complications of graft failure and improving clinical outcomes post bypass surgery. The Companyâs product under development includes MATLOC and MAR-FG-001. MATLOC is a lab-on-chip digital screening and diagnostic device platform being developed for quantitative chronic kidney disease (CKD) assessment. The MAR-FG-001 is a tumescent solution base for fat grafting procedures that is used for plastic and cosmetic surgeries in which fat is transferred from one area of the body to another to correct a defect, replace injured tissue, or to make cosmetic enhancements.
MARIZYME, INC. 
